1-Hydroxybenzotriazole → 2-(1,3-Dimethyl-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-5-yl)-N-[4-(trifluoromethyl)-1,3-thiazol-2-yl]acetamide
反応式
[CH3:1][N:2]1[C:7]2=[CH:8][S:9][C:10](C)=[C:6]2[C:5](=[O:12])[N:4]([CH3:13])[C:3]1=[O:14].[F:15][C:16]([F:24])([F:23])[C:17]1[N:18]=[C:19]([NH2:22])[S:20][CH:21]=1.CCN=C=NC[CH2:31][CH2:32]N(C)C.Cl.C1C=CC2N([OH:46])N=NC=2C=1>CN(C1C=CN=CC=1)C.ClCCCl>[CH3:1][N:2]1[C:10]2[S:9][CH:8]=[C:7]([CH2:31][C:32]([NH:22][C:19]3[S:20][CH:21]=[C:17]([C:16]([F:24])([F:23])[F:15])[N:18]=3)=[O:46])[C:6]=2[C:5](=[O:12])[N:4]([CH3:13])[C:3]1=[O:14]参加物
7
反応物 4
生成物 1
試薬・触媒・溶媒 2
実験手順
The title compound was prepared according to the general procedure (Method A) by coupling Intermediate 1 (100 mg, 0.393 mmol) with 4-(trifluoromethyl)-1,3-thiazol-2-amine (66 mg, 0.393 mmol) in the presence of EDCI hydrochloride (90 mg, 0.471 mmol), HOBt (16 mg, 0.118 mmol) and DMAP (5 mg, 0.039 mmol) in 1,2 dichloroethane (4 ml) to give 27 mg of the product as a white solid; 1H NMR (300 MHz, DMSO-d6) δ 3.18 (s, 3H), 3.46 (s, 3H), 4.05 (s, 2H), 7.07 (s, 1H), 7.91 (s, 1H), 12.70 (br s, 1H); APCI-MS (m/z) 404.97 (M+H)+.
出典と根拠
- ORDレコード
- ord-f2f002be385c43dab5743f6b12e5841b
- 出典データセット
- uspto-grants-2015_03
- 特許番号
- US08987278B2
反応ノート
読み込み中…